Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering

22 Jun 2018

Abstract excerpt

Human tissue kallikrein (KLK) proteases are hormone-like signaling molecules with important functions in cancer pathophysiology. KLK-related peptidase 6 (KLK6), specifically, is highly up-regulated in several types of cancer, where its increased activity promotes cancer invasion and metastasis. This characteristic suggests KLK6 as an attractive target for therapeutic interventions. However, inhibitors that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Coagulation, Bradykinin, Polyphosphates, and Angioedema
Share to Computational Drug Discovery Methods
Share to Phytochemical compounds biological activities

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29934309
DOI: 10.1074/jbc.ra117.000871

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineeringPMID 29934309Read ↗

A KLK6 Activity-Based Probe Reveals a Role for KLK6 Activity in Pancreatic Cancer Cell InvasionSemantic proximity Read ↗

Substrate specificity of human kallikreins 1 and 6 determined by phage displaySemantic proximity Read ↗

Kallikrein-related peptidases: mechanistic understanding for potential therapeutic targeting in cancerSemantic proximity Read ↗

The physiology and pathobiology of human kallikrein-related peptidase 6 (KLK6).Semantic proximity Read ↗

Kallikrein-related peptidases (KLKs) and the hallmarks of cancerSemantic proximity Read ↗

High-throughput Activity Reprogramming of Proteases (HARP)Semantic proximity Read ↗

Kallikrein-related peptidases represent attractive therapeutic targets for ovarian cancerSemantic proximity Read ↗

Designing peptide inhibitors targeting LRP6 co-receptor to restrict its association to DKK1; an Alzheimer’s disease therapeutic strategySemantic proximity Read ↗

Engineering selective amyloid precursor protein inhibitors by machine learning and deep mutational scanning.Semantic proximity Read ↗

Kallikrein-related peptidases (KLKs): a gene family of novel cancer biomarkersSemantic proximity Read ↗

Utility of Kallikrein-Related Peptidases (KLKs) as Cancer BiomarkersSemantic proximity Read ↗

KLK6‐regulated miRNA networks activate oncogenic pathways in breast cancer subtypesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.